Business Context and Reporting Period
Acrivon Therapeutics, Inc. (ACRV) is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines using its proprietary AP3 (Acrivon Predictive Precision Proteomics) platform. The platform utilizes phosphoproteomics to identify patient responders and optimize drug candidates. This summary covers the fiscal year ended December 31, 2025, as reported in the Form 10-K filed on March 19, 2026.
The company has no approved products and has not generated any revenue from product sales. Its operations are funded by capital raised through its IPO and private placements.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(77.9) million | $(80.6) million |
| Operating Expenses | $84.1 million | $89.2 million |
| Research & Development (R&D) | $60.0 million | $64.0 million |
| General & Administrative (G&A) | $24.1 million | $25.2 million |
| Cash, Cash Equivalents & Investments | $118.6 million | $181.6 million (Total Current Assets) |
| Accumulated Deficit | $(274.9) million | $(197.0) million |
| Net Cash Used in Operating Activities | $(63.7) million | $(65.7) million |
Note: The filing does not provide specific gross margin or operating margin percentages as the company has no revenue.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $2.7 million (3.3%) year-over-year, primarily driven by a reduction in operating expenses.
- R&D Expense Shift: Total R&D expenses decreased by $4.0 million. This was due to an $11.1 million decrease in costs for the lead program ACR-368 (due to fewer milestones and prioritization of endometrial cancer trials), partially offset by a $4.1 million increase in costs for the internally discovered program ACR-2316 following its Phase 1 initiation.
- Interest Income Decline: Interest income dropped from $9.2 million in 2024 to $6.5 million in 2025, reflecting changes in investment yields and accretion.
- Investment Portfolio: The company significantly reduced its investment portfolio, with short-term investments dropping from $139.7 million in 2024 to $77.1 million in 2025, while cash and cash equivalents remained relatively stable.
Guidance, Outlook, and Management Commentary
Clinical Pipeline Progress
- ACR-368 (Prexasertib): The Phase 2b trial in endometrial cancer (EC) showed a confirmed overall response rate (ORR) of 39% in Arm 1 (biomarker-positive patients) and 44% in patients with up to two prior lines of therapy. The company added Arms 3 and 4 to investigate "all-comer" serous EC patients, with and without ultra-low dose gemcitabine (ULDG) sensitization. The company plans a confirmatory trial combining ACR-368 with anti-PD-1.
- ACR-2316: Phase 1 monotherapy trial is in dose escalation. Initial data showed a favorable tolerability profile and clinical activity, including a confirmed partial response in EC and unconfirmed responses in SCLC and sqNSCLC.
- ACR-6840: An internally discovered CDK11 inhibitor is advancing in IND-enabling studies, with a planned filing in Q4 2026.
Liquidity and Capital Resources
As of December 31, 2025, the company held $118.6 million in cash, cash equivalents, and investments. Management believes this is sufficient to fund operations into the second quarter of 2027. The company expects to continue incurring significant losses and will require additional funding to support clinical development and potential commercialization.
Strategic Developments
- Companion Diagnostic: In February 2026 (subsequent to the reporting period), the company terminated its agreement with Akoya Biosciences and transitioned the ACR-368 OncoSignature testing to its own newly certified CLIA laboratory in Watertown, Massachusetts, gaining full control over the diagnostic.
- Licensing: In July 2025, the company obtained full release of Eli Lilly's right of first negotiation (ROFN) for ACR-368, granting Acrivon unencumbered global rights to partner or commercialize the asset.
Risks and Contingencies
- Regulatory Approval: Success depends on obtaining FDA approval for ACR-368 and ACR-2316, which is uncertain and subject to clinical trial outcomes.
- Capital Needs: The company has no revenue and relies on equity financing. Failure to raise additional capital could force curtailment of operations.
- Competition: The precision oncology space is competitive, with multiple companies developing CHK1/2 and WEE1 inhibitors.
Key Facts for Investor Verification
- Cash Runway: Verify the $118.6 million cash position and the management estimate of funding sufficiency through Q2 2027.
- ACR-368 Clinical Data: Confirm the interim ORR data (39-44%) in the Phase 2b endometrial cancer trial and the status of the new "all-comer" arms.
- OncoSignature Transition: Verify the operational status of the new in-house CLIA laboratory and the successful transition of testing from Akoya.
- ACR-2316 Progress: Monitor the Phase 1 dose escalation results and the establishment of the recommended Phase 2 dose.
- Future Financing: Assess the likelihood and terms of future capital raises required to bridge the gap to potential commercialization or partnership.